Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Genzyme
Femme et Homme Max 99 ans
Genzyme Europe B.V
MAJ Il y a 4 ans
Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure Phase 2 Study Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Study
The coprimary objectives of this study are to assess the recovery of contractility in akinetic myocardial segments that have received transplanted skeletal myoblasts as measured by echocardiogram, and...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme, a Sanofi Company
MAJ Il y a 4 ans
A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase)
To evaluate the antibody response to Aldurazyme in newly treated severe MPS I patients following an antigen-specific immunosuppressive regimen.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation Inc
MAJ Il y a 4 ans
An Exploratory, Open-Label Study of the Safety and Efficacy of High Dose or High Dosing Frequency Myozyme® (alglucosidase alfa) Treatment in Patients with Pompe Disease Who Do Not Have an Optimal Response to the Standard Dose Regimen
1. Evaluate the safety and efficacy of alternate alglucosidase alfa dosing regimens 2. Evaluate differences in efficacy in the 2 dosing arms
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
A Phase 3 Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Patients with Relapsing-Remitting Multiple Scleroris Who Have Relapsed On Therapy
The main objectives of study CAMMS32400507 is to compare the safety and efficacy of 2 annual cycles of 12 mg/day intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta-1a (Re...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe BV
MAJ Il y a 4 ans
A randomized, double-blind study of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with C.difficile-associated diarrhea
To compare the safety and tolerability of GT267-004 versus vancomycin, and GT267-004 versus metronidazole, in patients with Clostridium difficile-associated diarrhea (CDAD). To compare the effect of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Genzyme
MAJ Il y a 4 ans
GENZYME PREDICT : Essai de phase 3 évaluant l’efficacité du Plerixafor associé au G-CSF dans la mobilisation des cellules souches périphériques, chez des patients un lymphome non hodgkien, une maladie de hodgkin ou un myélome multiple. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Plerixafor and G−CSF for the mobilisation of peripheral blood stem cells for autologous stem cell transplantation in patients with non−hodgkin's lymphoma (NHL), hodgkin's disease (HD) or multiple myel...
Pays
France
Organes
Lymphomes hodgkinien (maladie de Hodgkin)
,
Lymphomes non hodgkinien
,
Myélomes
Spécialités
Autres (cryothérapie, radiofréquence, homéopathie,...)
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Corporation
MAJ Il y a 4 ans
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients with RRMS with Disease Activity on Prior DMT Estudio para evaluar la eficacia, la seguridad y la tolerabilidad de alemtuzumab en pacientes pediátricos con esclerosis múltiple recurrente remitente (EMRR) con actividad de la enfermedad en la terapia previa modificadora de la enfermedad (TME)
To evaluate the efficacy, safety, and tolerability of alemtuzumab (IV) in pediatric patients from 10 to <18 years of age with RRMS who have disease activity on prior DMT. Evaluar la eficacia, se...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe B.V
MAJ Il y a 4 ans
A Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study to Demonstrate the Superiority of Matrix-induced Autologous Chondrocyte Implantation (MACI® implant) versus Arthroscopic Microfracture for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle including the Trochlea
The objective of this study is to demonstrate superior efficacy and evaluate the safety of MACI implant compared with arthroscopic microfracture in the treatment of patients (aged 18 to 55 years old) ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Genzyme Europe BV
MAJ Il y a 4 ans
Phase II Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Alemtuzumab (CAMPATH, MabCampath) in Patients with Previously Treated B Cell Chronic Lymphocytic Leukemia
The primary objective of this study is to determine best disease response to treatment with CAMPATH administered subcutaneously (SC) for up to 18 weeks in patients with B-Cell Chronic Lymphocytic Leuk...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
6